European Community SYStemic VASculitis TRIALs group

ISRCTN ISRCTN03001669
DOI https://doi.org/10.1186/ISRCTN03001669
Secondary identifying numbers N/A
Submission date
31/01/2006
Registration date
21/02/2006
Last edited
15/08/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr David Jayne
Scientific

Box 118
Renal Unit
Addenbrookes Hospital
Cambridge
CB2 2QQ
United Kingdom

Phone +44 (0)1223 217259
Email dj106@cam.ac.uk

Study information

Study designInterventional, randomised, controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymECSYSVASTRIAL
Study objectivesPlasma exchange is superior to high dose intravenous methylprednisolone in the treatment of severe renal vasculitis.
Ethics approval(s)Received from the Cambridge Local Research Ethics Committee in March 1995.
Health condition(s) or problem(s) studiedANCA associated vasculitis
InterventionPlasma exchange versus high dose intravenous methyl prednisolone
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Methyl prednisolone
Primary outcome measureRenal recovery at three months
Secondary outcome measuresEnd stage renal disease at one year, severe adverse events
Overall study start date01/03/1995
Completion date31/01/2001

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants150
Key inclusion criteria1. New diagnosis of Wegener granulomatosis (WG), micropolyarteritis (MP) or its renal-limited variant, in accordance with the Chapel Hill Consensus criteria, with active vasculitis, as indicated by the presence of active necrotising glomerulonephritis on renal biopsy
2. Anti-neutrophilic cytoplasmic antibodies (ANCA) positivity: either a typical cytoplasmic-ANCA pattern by immunofluorescence test (IIF), and/or positivity in the proteinase-3 enzyme-linked immunosorbent assay (Pr3 ELISA), or positivity in the myeloperoxidase (MPO) ELISA, with or without perinuclear-ANCA (ANCA result will be confirmed by a nominated reference laboratory)
3. Biopsy-proven necrotising and/or crescentic glomerulonephritis, in the absence of another defined glomerulopathy, with severe renal impairment as defined by either:
3.1. Oliguria (less than 400 ml/24 hr) or
3.2. Intention to commence dialysis within 48 hours of admission
Key exclusion criteria1. Aged less than 18 or over 80
2. Inadequate contraception in women of child-bearing age
3. Pregnancy
4. Usually exclude patients with previous malignancy (unless agreed with trial coordinators)
5. Hepatitis B antigenaemia or detectable anti-hepatitis C virus antibody
6. Known anti-human immunodeficiency virus (anti-HIV) (HIV testing is not a requirement for this trial)
7. Diagnosis of Churg-Strauss syndrome, Henoch-Schonlein purpura, rheumatoid vasculitis, mixed essential cryoglobulinaemia, systemic lupus erythematosus, or the presence of circulating anti-glomerular basement membrane (anti-GBM) antibodies and linear gamma G immunoglobulin (IgG) staining of the GBM on renal biopsy, with intent to treat as anti-GBM mediated nephritis
8. Life-threatening non-renal manifestations of vasculitis, including alveolar haemorrhage requiring mechanical ventilation within 24 hours of admission
9. On dialysis for more than two weeks prior to referral
10. Significant baseline renal impairment: creatinine greater than 200 mmol/l one year or more before presentation
11. A second clearly defined cause of renal failure (e.g. urinary tract obstruction; not acute tubular necrosis [ATN])
12. Previous episode of biopsy-proven necrotising and/or crescentic glomerulonephritis
13. Intravenous methylprednisolone (IVMeP), plasma exchange (PE) or pulsed intravenous cyclophosphamide within the preceding year
14. More than two weeks treatment with oral cyclophosphamide (Cyc) or azathioprine (Aza)
15. More than three months treatment with oral corticosteroids (OCS)
16. Allergy to study medications (excluding prophylactic agents)
17. Previous IVMeP therapy, which exceeds a single dose of 500 mg prior to referral to the participating centre
Date of first enrolment01/03/1995
Date of final enrolment31/01/2001

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Box 118
Cambridge
CB2 2QQ
United Kingdom

Sponsor information

Addenbrookes Hospital NHS Trust (UK)
Hospital/treatment centre

Addenbrookes Hospital
Hills road
Cambridge
CB2 2QQ
England
United Kingdom

ROR logo "ROR" https://ror.org/055vbxf86

Funders

Funder type

Government

European Union (Belgium) - Biomedical and Health Research Programme (BIOMED) (contract number BMH4-CT97-2328)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 01/07/2007 Yes No